Responsive BP reduction within minutes in the postoperative clinical setting1,3
91.8% of patients on CLEVIPREX achieved treatment success*3
The primary endpoint was the incidence of treatment failure, defined as the inability to decrease SBP by ≥15% from baseline or the discontinuation of study treatment for any reason within the 30-minute period after study drug initiation.3
*Treatment success was defined as a reduction of SBP of ≥15% from baseline within the 30-minute period from study drug initiation.
†The decrease in placebo group SBP reflects the number of placebo patients (N=49 at baseline) who bailed out during the 30-minute infusion period (N=10 remaining at 30 minutes).